Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Alivus Life Sciences's Net-Net Working Capital for the quarter that ended in Jun. 2026 was ₹0.00.
The industry rank for Alivus Life Sciences's Net-Net Working Capital or its related term are showing as below:
NSE:ALIVUS's Price-to-Net-Net-Working-Capital is ranked worse than 66.41% of 393
companies
in the Drug Manufacturers industry
Industry Median: 8.18
vs NSE:ALIVUS: 13.05
Alivus Life Sciences (NSE:ALIVUS) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Alivus Life Sciences Net-Net Working Capital Related Terms
Alivus Life Sciences Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences Net-Net Working Capital Chart
NSE:ALIVUS vs ZTS: Net-Net Working Capital Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of ₹0.00 mean?
Alivus Life Sciences (NSE:ALIVUS) has a Net-Net Working Capital of ₹0.00 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Alivus Life Sciences According to the industry distribution chart, Alivus Life Sciences ranks #261 out of 393 companies in the Drug Manufacturers industry, placing it in the top 66.4%.
Is Alivus Life Sciences' Net-Net Working Capital too high?
Alivus Life Sciences' current Net-Net Working Capital is ₹0.00. Based on the distribution chart, Alivus Life Sciences ranks #261 out of 393 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alivus Life Sciences has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Net-Net Working Capital compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #261 out of 393 companies for Net-Net Working Capital. This places Alivus Life Sciences in the lower half of its industry. The industry median Net-Net Working Capital is 8.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 8.18, based on 393 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Alivus Life Sciences For the Drug Manufacturers industry, the median Net-Net Working Capital is 8.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Net-Net Working Capital is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,035.87, compared to a current price of ₹1,366.10 — trading 31.9% above its estimated fair value. The current Net-Net Working Capital is ₹0.00. Alivus Life Sciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Net-Net Working Capital is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,366.10 is trading 31.9% above its estimated GF Value™ of ₹1,035.87.
GuruFocus considers Alivus Life Sciences to be Significantly Overvalued.
Key valuation signals for NSE:ALIVUS:
Net-Net Working Capital: ₹0.00
GF Value™: ₹1,035.87 vs. price of ₹1,366.10 (31.9% above fair value)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
80GF Score
Get the complete analysis for NSE:ALIVUS
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
